Three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy ...

Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...

Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science ...

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

As BIOSPAIN 2026 comes to end, delve into what as been at the center of this edition's discussion: what comes after we have ...

Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find ...

September is often a strong month for the biopharma sector as the industry returns from the summer lull, keen on forging biotech deals.

The companies ADARx Pharmaceuticals, Electra Therapeutics, and Enveda bagged the biggest biotech funding rounds overall in ...

Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability ...

Look into Spain's biotech, an ecosystem that has matured and transforms promissing science into ventures but faces challenges ...

If you were to look back just a little over two years ago to the start of 2021, then putting money into a biotech company seemed like a pretty safe bet. After all, the COVID-19 pandemic had shined a ...

According to Julien Ettersperger, Delégué Général (CEO) of Medicen Paris Region – the competitiveness cluster dedicated to healthcare in the Île-de-France region – the Paris region has established ...